#PRESS Pivotal Week 52 results from the #AscendisPharma randomized double-blind, placebo-controlled ApproaCH Trial for our investigational product candidate in children with #achondroplasia has been published in JAMA Pediatrics, a journal of the American Medical Association. Learn more: https://lnkd.in/gF4_7gm8 DOI: 10.1001/jamapediatrics.2025.4771
Ascendis Pharma
Forskning inden for bioteknologi
Hellerup, Capital Region of Denmark 88.458 følgere
Committed to making a meaningful difference for patients
Om os
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
- Websted
-
http://www.ascendispharma.com
Eksternt link til Ascendis Pharma
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 1.001 – 5.000 medarbejdere
- Hovedkvarter
- Hellerup, Capital Region of Denmark
- Type
- Aktieselskab
- Grundlagt
- 2007
- Specialer
- Endocrinology, Oncology, Drug Development, Innovation, Globalization og TransCon Technology
Beliggenheder
-
Primær
Se ruten
Tuborg Boulevard 12
Hellerup, Capital Region of Denmark 2900, DK
Medarbejdere hos Ascendis Pharma
Opdateringer
-
#PRESS #AscendisPharma announces our Q3 2025 results and provides a business update. Learn more on the Investors & News section of our website.
-
-
During #FamilyCaregiversMonth, #AscendisPharma recognizes caregivers everywhere who offer unwavering support and compassion. Thank you for the vital role you play in the lives of others every day.
-
-
#HCPs At this year’s American Society of Nephrology #KidneyWk, 3-year renal data from the #AscendisPharma Phase 2 PaTH Forward and Phase 3 PaTHway trials in adults with #hypoparathyroidism will be presented.
-
-
#HCPs #AscendisPharma is attending this year’s #KidneyWk in Houston, presented by the American Society of Nephrology. We look forward to connecting with industry professionals at the world’s premiere kidney meeting.
-
-
📸 Our #AscendisPharma team had a wonderful time at the Little Legs Big Heart Skeletal Dysplasia Conference in West Palm Beach this past weekend! Thank you to The Little Legs Big Heart Foundation for organizing such an inspiring and educational event.
-
-
Today, #AscendisPharma supports #InternationalDwarfismAwarenessDay and the efforts to broaden awareness of the history, pride and empowerment of the dwarfism community.
-
-
In recognition of #InternationalDwarfismAwarenessDay on October 25, #AscendisPharma is spotlighting our very own Annette Arnberg, Senior Global Medical Director, who is sharing her commitment to advancing care and support for individuals with #achondroplasia. Join us as we stand with the dwarfism community to honor their strength and resilience, and to help raise awareness that drives better understanding and care.
-
-
#AscendisPharma is attending the 2025 Little Legs Big Heart Skeletal Dysplasia Conference: Connecting Hearts, Minds & Medicine! This event brings together families, advocates, and healthcare professionals to share knowledge, build connections, and support the #skeletaldysplasia community. We are committed to listening to, learning from, and collaborating with the skeletal dysplasia community to help advance meaningful progress for people living with #rarediseases.
-
-
During the recent celebration of our U.S. team’s new and expanded office space in Princeton, #AscendisPharma was honored to welcome Pamela Gavin from the National Organization for Rare Disorders (NORD), who presented the Rare Impact Award we received earlier this year. As a dynamic, growing biopharmaceutical company, we look forward to continuing fulfilling our mission to make a meaningful difference in patients’ lives. Learn more about Ascendis: https://lnkd.in/eWaKtMbV
-
Tilknyttede sider
Tilsvarende sider
Finansiering
Ascendis Pharma
8 runder i alt
Læs mere på crunchbase
Seneste runde
Post IPO-egenkapital
Eksternt Crunchbase-link til seneste finansieringsrunde
300.000.000,00 US$